Analyst Price Target is $25.00
▲ +69.38% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Progyny in the last 3 months. The average price target is $25.00, with a high forecast of $43.00 and a low forecast of $17.00. The average price target represents a 69.38% upside from the last price of $14.76.
Current Consensus is
Hold
The current consensus among 13 contributing investment analysts is to hold stock in Progyny. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Read More